EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na iD, Kwang Pyo Kim iD, Seung Hyeok Seok iD

Molecular Oncology · 2025-08 · 19 (8) · 2233-2248

DOI: 10.1002/1878-0261.13817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 12.02.2025. Verfasst von Yeon Ji Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Translational Immunology Lab, Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Proteome, Biomarkers, Tumor, Disease Progression, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Seoul National University Hospital, Korea Drug Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune status critically affects cancer progression and therapy responses. This study aimed to identify plasma proteome changes in immunosuppressive cancer and potential biomarkers predicting systemic immunosuppression. Mouse models of syngeneic breast tumors (benign 67NR and malignant 4T1) were used to collect plasma samples. Plasma samples from naive mice and both early‐ and late‐stage tumor‐bearing mice were subjected to liquid chromatography–mass spectrometry (LC–MS) analysis. 4T1‐bearing mice showed systemic immunosuppression characterized by significant generation of myeloid‐derived suppressor cells (MDSCs) as early as 7 days after tumor implantation, unlike 67NR tumors. LC–MS identified 1086 proteins across the five experimental groups, with 27 proteins showing group‐specific expression in 4T1 blood compared with 67NR blood. Immune‐related proteins osteopontin, lactotransferrin, calreticulin, and peroxiredoxin 2 were selected as potential biomarkers of MDSC‐producing breast cancer. These markers were expressed in cancer cells or MDSC in the 4T1 model, and osteopontin and peroxiredoxin 2 were associated with low survival probability and high recurrence in patients with triple‐negative breast cancer. Our findings suggest that MDSC‐producing immunosuppressive cancers have unique plasma proteomes, offering additional insights into cancer immune status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomeBiomarkers, TumorDisease ProgressionBreast NeoplasmsAnimalsFemaleMiceHumansMice, Inbred BALB CMyeloid-Derived Suppressor CellsCell Line, Tumor

Stichwörter der Autor:innen

biomarkerimmunosuppressive cancermyeloid‐derived suppressor cellsplasmaproteomics

Substanzen

ProteomeBiomarkers, Tumor

Autor:innen und Institutionen

  • Translational Immunology Lab, Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
  • Department of Applied Chemistry, Institute of Natural Science, Kyung Hee University, Yongin, Republic of Korea.
  • Macrophage Lab, Department of Microbiology and Immunology, and Institute of Endemic Disease, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Immunology Core Facility, Department of Translational Research Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.

ORCID-Profile: Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok

Förderung

  • National Research Foundation of Korea
  • Seoul National University Hospital
  • Korea Drug Development Fund

Zitieren

APA

Park, Y. J., Oh, J. W., Chung, H., Kwon, J. W., Na, Y. R., Kim, K. P., & Seok, S. H. (2025). Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression. Molecular Oncology, 19(8), 2233-2248. https://doi.org/10.1002/1878-0261.13817

Vancouver

Park YJ, Oh JW, Chung H, Kwon JW, Na YR, Kim KP, et al. Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression. Molecular Oncology. 2025;19(8):2233-2248. doi:10.1002/1878-0261.13817

BibTeX
@article{Park2025,
  author = {Park, Yeon Ji and Oh, Jae Won and Chung, Hyewon and Kwon, Jung Won and Na, Yi Rang and Kim, Kwang Pyo and Seok, Seung Hyeok},
  title = {Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression},
  journal = {Molecular Oncology},
  year = {2025},
  volume = {19},
  number = {8},
  pages = {2233--2248},
  doi = {10.1002/1878-0261.13817}
}
Kostenlos starten →